Filing Flows › Cytek Biosciences (CTKB) › Q4 2025
Cytek Biosciences (CTKB) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Cytek Biosciences (CTKB) reported revenue of $62.1M for the fourth quarter 2025 (Q4 2025), +8% from a year earlier and +19% from the quarter before. Operating margin was -9.0%, net loss $44.1M (70.9% of revenue).
Cytek Biosciences, Q4 2025: revenue $62.1M (+8% year over year), operating margin -9.0%, net loss $44.1M, operating cash flow −$771K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $62.1M | +19% | +8% |
| Operating profit | −$5.6M | — | — |
| Net earnings | −$44.1M | — | — |
| Operating cash flow | −$771K | — | — |
What changed
Revenue was $62.1M in Q4 2025, up 8% year over year and up 19% from the previous quarter. Product was the largest line at 75% of revenue.
Gross margin was 52.9%, down 5.6 points from a year earlier. Operating costs exceeded revenue by $5.6M, an operating margin of -9.0%. Operating expenses grew 25% against revenue growth of 8%. The fastest-growing cost line was General & admin (+81%). The quarter ended with a net loss of $44.1M, wider than the previous quarter's $5.5M loss. Non-operating items added $1.6M, -39% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$771K. Non-cash charges added back $1.9M of depreciation and amortization and $5.5M of share-based compensation. Working capital and other items added $35.9M. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$1.8M.
Questions
What was Cytek Biosciences' revenue in the fourth quarter 2025?
Cytek Biosciences (CTKB) reported revenue of $62.1M for the fourth quarter 2025 (Q4 2025), +8% from a year earlier and +19% from the quarter before.
Was Cytek Biosciences profitable in the fourth quarter 2025?
Operating loss was $5.6M (-9.0% of revenue) and net loss $44.1M.
Source: Cytek Biosciences 10-K on SEC EDGAR.